SELLAS Life Sciences Group, Inc. (SLS) shareholders
Close on Nov 17, 2026Market cap $3.87BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 15,872,685 | 7.90% | 13G (passive) amendment | Sep 30, 2026 |
| State Street Corporation | 10,373,074 | 5.10% | 13G (passive) | Sep 30, 2026 |
| Vanguard Capital Management | 9,666,278 | 5.19% | 13G (passive) | Jun 30, 2026 |
| Moez Kassam Joint filing with Anson Funds Management LP (8.30%), Anson Management GP LLC (8.30%) and 3 more | 7,579,095 | 8.30% | 13G (passive) | Mar 31, 2025 |
| Anson Advisors Inc. Joint filing with Anson Funds Management LP (5.70%), Anson Management GP LLC (5.70%) and 3 more | 6,032,938 | 5.70% | 13G (passive) | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SLS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 15,070,302 | 7.46% | $222.44M | +2,871,892 | 0.00% |
| State Street Corp | 12,996,558 | 6.44% | $191.83M | +4,600,202 | 0.01% |
| Vanguard Capital Management LLC | 8,226,105 | 4.07% | $121.42M | +700,176 | 0.00% |
| Geode Capital Management, LLC | 4,884,175 | 2.42% | $72.11M | +971,569 | 0.00% |
| Anson Funds Management LP | 4,500,000 | 2.23% | $66.42M | New | 3.94% |
| Jones Financial Companies Lllp | 2,304,561 | 1.14% | $28.55M | +629,484 | 0.01% |
| Vanguard Portfolio Management LLC | 2,161,099 | 1.07% | $31.90M | +698,293 | 0.00% |
| Susquehanna International Group, Llp | 2,050,597 | 1.02% | $30.27M | +1,653,541 | 0.00% |
| Northern Trust Corp | 1,619,928 | 0.80% | $23.91M | +343,944 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,335,166 | 0.66% | $19.71M | +132,327 | 0.00% |
| UBS Group AG | 1,252,757 | 0.62% | $18.49M | +507,338 | 0.00% |
| Morgan Stanley | 1,236,261 | 0.61% | $18.25M | −100,032 | 0.00% |
| Dagco, Inc. | 1,232,433 | 0.61% | $18.19M | +203,653 | 3.36% |
| Bnp Paribas Arbitrage, Snc | 1,072,022 | 0.53% | $15.82M | +1,025,006 | 0.01% |
| Bank Of America Corp /De/ | 787,949 | 0.39% | $11.63M | +146,266 | 0.00% |
| Wellington Management Group Llp | 597,309 | 0.30% | $8.82M | +252,531 | 0.00% |
| Goldman Sachs Group Inc | 585,035 | 0.29% | $8.64M | +29,122 | 0.00% |
| Charles Schwab Investment Management Inc | 565,008 | 0.28% | $8.34M | +84,404 | 0.00% |
| Bank of New York Mellon Corp | 530,025 | 0.26% | $7.82M | +51,659 | 0.00% |
| Jane Street Group, LLC | 508,429 | 0.25% | $7.50M | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 192 | 74M | 36.5% | 63 / 78 | 26 / 27 | 25M | 5M |
| Q1 2026 | 160 | 54M | 26.7% | 67 / 53 | 18 / 16 | 31M | 4M |
| Q4 2025 | 112 | 35M | 17.6% | 28 / 49 | 19 / 9 | 11M | 9M |
| Q3 2025 | 94 | 33M | 16.3% | 21 / 31 | 18 / 5 | 9M | 3M |
| Q2 2025 | 79 | 27M | 13.3% | 40 / 22 | 7 / 6 | 20M | 8M |
| Q1 2025 | 45 | 14M | 7.1% | 18 / 18 | 3 / 4 | 8M | 0M |
| Q4 2024 | 31 | 6M | 3.1% | 6 / 10 | 5 / 8 | 1M | 0M |
| Q3 2024 | 33 | 5M | 2.7% | 9 / 10 | 5 / 4 | 2M | 0M |
| Q2 2024 | 30 | 4M | 2.0% | 9 / 12 | 2 / 9 | 1M | 5M |
| Q1 2024 | 30 | 8M | 3.8% | 7 / 8 | 6 / 8 | 5M | 1M |
| Q4 2023 | 31 | 4M | 1.7% | 8 / 13 | 3 / 5 | 2M | 1M |
| Q3 2023 | 28 | 3M | 1.4% | 5 / 9 | 6 / 2 | 0M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
113 funds held SLS in Q2 2026, 79% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SLS | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 8,654,720 | 4.29% | $127.74M | 1.19% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 5,906,922 | 2.93% | $87.19M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,928,335 | 2.44% | $72.74M | 0.09% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,134,837 | 1.06% | $31.51M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,063,963 | 1.02% | $20.66M | 0.06% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,742,114 | 0.86% | $25.71M | 0.17% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 883,026 | 0.44% | $8.22M | 0.05% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 881,240 | 0.44% | $8.20M | 0.02% | May 31, 2026 |
| iShares Micro-Cap ETF | 632,184 | 0.31% | $9.33M | 0.61% | Jun 30, 2026 |
| Vanguard U.S. Momentum Factor ETF | 604,612 | 0.30% | $5.63M | 0.31% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 458,889 | 0.23% | $4.59M | 0.06% | Jul 31, 2026 |
| Master Small Cap Index Series | 343,271 | 0.17% | $5.07M | 0.08% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 318,615 | 0.16% | $2.97M | 0.00% | May 31, 2026 |
| Direxion Daily S&P Biotech Bull 3X Shares | 293,250 | 0.15% | $2.94M | 0.59% | Jul 31, 2026 |
| Invesco Dorsey Wright SmallCap Momentum ETF | 274,459 | 0.14% | $2.56M | 0.61% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Angelos M. Stergiou | President and CEO, Director | 1,976,604 | 0.98% | Jun 18, 2026 |
| John Thomas Burns | CFO | 609,254 | 0.30% | Jan 9, 2026 |
| Dragan Cicic | SVP, Chief Development Officer | 557,805 | 0.28% | Jan 9, 2026 |
| David A. Scheinberg | Director | 73,082 | 0.04% | Jan 9, 2026 |
| Nostrand Robert L. Van | Director | 82,900 | 0.04% | Jan 9, 2026 |
| Katherine Bach Kalin | Director | 154,400 | 0.08% | Jan 9, 2026 |
| John Varian | Director | 72,900 | 0.04% | Jan 9, 2026 |
| Jane Wasman | Director | 92,900 | 0.05% | Jan 9, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Angelos M. Stergiou President and CEO, Director | Jun 16, 2026 | Award | +1,065,000 | – | – | 1,759,183 |
| Dragan Cicic SVP, Chief Development Officer | Jan 7, 2026 | Award | +300,000 | – | – | 557,805 |
| David A. Scheinberg Director | Jan 7, 2026 | Award | +50,000 | – | – | 73,082 |
| John Thomas Burns CFO | Jan 7, 2026 | Award | +300,000 | – | – | 554,327 |
| John Varian Director | Jan 7, 2026 | Award | +50,000 | – | – | 72,900 |
| Nostrand Robert L. Van Director | Jan 7, 2026 | Award | +50,000 | – | – | 82,900 |
| Katherine Bach Kalin Director | Jan 7, 2026 | Award | +50,000 | – | – | 154,400 |
| Jane Wasman Director | Jan 7, 2026 | Award | +50,000 | – | – | 92,900 |
| John Thomas Burns CFO | Dec 3, 2025 | Other | −58,592 | $1.50 | $87.89K | 254,327 |
| Dragan Cicic SVP, Chief Development Officer | Dec 3, 2025 | Other | −63,800 | $1.50 | $95.70K | 257,805 |
| Angelos M. Stergiou President and CEO, Director | Dec 3, 2025 | Other | −187,066 | $1.50 | $280.60K | 686,966 |
| Katherine Bach Kalin Director | Nov 19, 2025 | Buy | +63,400 | $1.59 | $100.81K | 104,400 |
| Nostrand Robert L. Van Director | Jun 12, 2025 | Buy | +10,000 | $1.48 | $14.80K | 20,400 |
| Jane Wasman Director | May 30, 2025 | Buy | +20,000 | $1.69 | $33.80K | 30,400 |
| Katherine Bach Kalin Director | May 22, 2025 | Buy | +20,000 | $1.80 | $36.00K | 41,000 |
| John Varian Director | Jan 10, 2025 | Award | +12,500 | – | – | 22,900 |
| Jane Wasman Director | Jan 10, 2025 | Award | +12,500 | – | – | 22,900 |
| Dragan Cicic SVP, Chief Development Officer | Jan 10, 2025 | Award | +113,000 | – | – | 228,328 |
| Dragan Cicic SVP, Chief Development Officer | Jan 10, 2025 | Award | +81,300 | – | – | 309,628 |
| Angelos M. Stergiou President and CEO, Director | Jan 10, 2025 | Award | +257,000 | – | – | 615,132 |
| Angelos M. Stergiou President and CEO, Director | Jan 10, 2025 | Award | +243,900 | – | – | 859,032 |
| Katherine Bach Kalin Director | Jan 10, 2025 | Award | +12,500 | – | – | 21,000 |
| John Thomas Burns CFO | Jan 10, 2025 | Award | +81,300 | – | – | 299,062 |
| John Thomas Burns CFO | Jan 10, 2025 | Award | +113,000 | – | – | 217,762 |
| Nostrand Robert L. Van Director | Jan 10, 2025 | Award | +12,500 | – | – | 22,900 |
| David A. Scheinberg Director | Jan 10, 2025 | Award | +12,500 | – | – | 23,082 |
| John Thomas Burns CFO | Dec 4, 2024 | Other | −7,165 | $1.13 | $8.10K | 104,762 |
| Dragan Cicic SVP, Chief Development Officer | Dec 4, 2024 | Other | −8,256 | $1.13 | $9.33K | 115,328 |
| Angelos M. Stergiou President and CEO, Director | Dec 4, 2024 | Other | −28,289 | $1.13 | $31.97K | 358,132 |
| Barbara A. Wood EVP, Gen. Counsel, Corp. Sec. | Jan 22, 2024 | Award | +35,000 | – | – | 117,225 |
| Angelos M. Stergiou President and CEO, Director | Jan 22, 2024 | Award | +159,000 | – | – | 376,421 |
| Robert Francomano Chief Commercial Officer | Jan 22, 2024 | Award | +20,000 | – | – | 40,918 |
| John Thomas Burns CFO | Jan 22, 2024 | Award | +47,000 | – | – | 101,927 |
| Nostrand Robert L. Van Director | Jan 22, 2024 | Award | +6,000 | – | – | 10,400 |
| John Varian Director | Jan 22, 2024 | Award | +6,000 | – | – | 10,400 |
| Jane Wasman Director | Jan 22, 2024 | Award | +6,000 | – | – | 10,400 |
| David A. Scheinberg Director | Jan 22, 2024 | Award | +6,000 | – | – | 10,582 |
| Katherine Bach Kalin Director | Jan 22, 2024 | Award | +6,000 | – | – | 8,500 |
| Barbara A. Wood EVP, Gen. Counsel, Corp. Sec. | Dec 6, 2023 | Other | −4,119 | $1.08 | $4.45K | 82,225 |
| John Thomas Burns CFO | Dec 6, 2023 | Other | −2,929 | $1.08 | $3.16K | 54,927 |
| Robert Francomano Chief Commercial Officer | Dec 6, 2023 | Other | −1,082 | $1.08 | $1.17K | 20,918 |
| Angelos M. Stergiou President and CEO, Director | Dec 6, 2023 | Other | −12,268 | $1.08 | $13.25K | 217,421 |
| Robert Francomano Chief Commercial Officer | Feb 2, 2023 | Award | +12,000 | – | – | 12,000 |
| David A. Scheinberg Director | Feb 2, 2023 | Award | +2,500 | – | – | 4,582 |
| John Thomas Burns CFO | Feb 2, 2023 | Award | +20,000 | – | – | 49,347 |
| Angelos M. Stergiou President and CEO, Director | Feb 2, 2023 | Award | +58,000 | – | – | 219,689 |
| Barbara A. Wood EVP, Gen. Counsel, Corp. Sec. | Feb 2, 2023 | Award | +20,000 | – | – | 76,344 |
| Jane Wasman Director | Feb 2, 2023 | Award | +2,500 | – | – | 4,400 |
| Nostrand Robert L. Van Director | Feb 2, 2023 | Award | +2,500 | – | – | 4,400 |
| Katherine Bach Kalin Director | Feb 2, 2023 | Award | +2,500 | – | – | 2,500 |
| John Varian Director | Feb 2, 2023 | Award | +2,500 | – | – | 4,400 |
| Barbara A. Wood EVP, Gen. Counsel, Corp. Sec. | Dec 5, 2022 | Sale | −2,153 | $2.59 | $5.58K | 56,344 |
| Angelos M. Stergiou President and CEO, Director | Dec 5, 2022 | Sale | −6,494 | $2.61 | $16.95K | 161,689 |
| John Thomas Burns Senior VP, Finance & CAO | Dec 5, 2022 | Sale | −1,159 | $2.59 | $3.00K | 29,347 |
| John Varian Director | Jan 31, 2022 | Award | +1,900 | – | – | 1,900 |
| Nostrand Robert L. Van Director | Jan 31, 2022 | Award | +1,900 | – | – | 1,900 |
| John Thomas Burns Senior VP, Finance & CAO | Jan 31, 2022 | Award | +9,600 | – | – | 27,244 |
| David A. Scheinberg Director | Jan 31, 2022 | Award | +1,900 | – | – | 2,082 |
| Angelos M. Stergiou President and CEO, Director | Jan 31, 2022 | Award | +44,000 | – | – | 165,167 |
| Jane Wasman Director | Jan 31, 2022 | Award | +1,900 | – | – | 1,900 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of SELLAS Life Sciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 403,160 shares on Sep 1, 2026 over the last 90 days.
See a number that looks wrong?